/

Società

Ec

Non verificato

Eccogene

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati

01/06/2026

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Eventi

Industria

Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026

Fonte

Emittente

1.00

0

16/03/2026

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Cardiologia

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity

Fonte

Emittente

1.00

0

10/02/2026

Biotecnologia

Farmaceutica

Sanità

Salute

Fitness

Medicina - Varie

Industria

Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China

Fonte

Emittente

1.00

0

16/12/2025

Industria

Scienza

Cardiologia

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0